{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-043776","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.956387+00:00","generated_at":"2026-06-04T00:07:45.581609+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVITA Medical cuts Q1 2024 revenue guidance to $11.0-$11.3M from prior $14.8-$15.6M","bullets":["Expected Q1 commercial revenue $11.0M-$11.3M vs prior guidance $14.8M-$15.6M.","Full-year 2024 revenue guidance reaffirmed at lower end of $78.5M-$84.5M.","Slower new account conversion: 73 accounts added since June 2023 vs expected 135 by March 2024.","Launched PermeaDerm in March; RECELL GO launch upcoming.","Q1 2024 earnings call scheduled for May 13, 2024 after market close."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-043776","json":"https://secwatch.observer/filing/0000950170-24-043776.json","markdown":"https://secwatch.observer/filing/0000950170-24-043776.md","text":"https://secwatch.observer/filing/0000950170-24-043776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/0000950170-24-043776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/rcel-20240410.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:07:45.581609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e3ab76c7eaae06b87ba599fd8f3fbe6bacd1b9f","claim":"AVITA Medical, Inc. reported first quarter of 2024 results: revenue US$11.0 million to US$11.3 million. Guidance lowered.","evidence_excerpt":"previously provided guidance of US$78.5 million to US$84.5 million. For the quarter ended March 31, 2024, AVITA Medical now expects commercial revenue to be in the range of US$11.0 million to US$11.3 million. This range is below the previously provided revenue guidance of US$14.8 million to US$15.6 million. The revision in guidance is attributable to a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/0000950170-24-043776-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"US$11.0 million to US$11.3 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}